Catching lung cancer early enables surgical tumor removal, while routine screening and newer therapies improve patient outcomes.
RT’s Three Key Takeaways:
- Early Surgical Resection: Detecting non-small cell lung cancer (NSCLC) at an early stage allows clinicians to perform a curative surgical resection of the tumor before advanced symptoms develop, according to Stony Brook Medicine.
- Advances in Targeted Therapies: Patient survival has improved due to modern immunotherapy and targeted therapies, particularly among individuals with actionable tumor mutations that appear more often in light smokers and never-smokers.
- Expanded Screening Recommendations: Increasing routine lung cancer screening for high-risk adults between the ages of 50 and 80 who have at least a 20-pack-year smoking history is essential to saving lives, healthcare experts reported.
Catching non-small cell lung cancer (NSCLC) in its initial stages remains critical for clinical intervention, yet the majority of cases continue to be diagnosed only after patients exhibit symptoms of advanced disease, according to an expert announcement from Stony Brook Medicine.
When NSCLC is identified early, clinicians can pursue surgical intervention with the goal of complete recovery, rather than managing late-stage disease progression. “If NSCLC is caught early, the approach remains to perform a ‘curative resection’ of the cancerous lesion”, said Amna Sher, MD, associate professor of medicine in the division of hematology and oncology at Stony Brook Medicine and clinician on the lung cancer and chest disease team at the Stony Brook Cancer Center.
Improvements in Targeted Therapies and Immunotherapy
Even for patients diagnosed later, survival outcomes have shown measurable progress in recent years through the development of novel targeted therapies and immunotherapy, according to Dr Sher.
Patients who harbor specific actionable mutations within their tumors have experienced improved outcomes with these precision treatments, a characteristic that Stony Brook Medicine noted is more prevalent among individuals who are light smokers, or who have never smoked.
Expanding High-Risk Screening to Save Lives
To ensure more patients qualify for early surgical treatment, Dr Sher emphasized that broader lung cancer screening is essential to lower mortality rates across healthcare systems.
Current medical guidelines recommend annual screening for individuals between 50 and 80 years of age who have a history of smoking 20 pack-years or more.
